Global Lisinopril Market – Industry Trends and Forecast to 2030

1. Global Lisinopril Market – Industry Trends and Forecast to 2030 Lisinopril Market Analysis and Size The increase in the prevalence of Hypertension and other cardiovascular diseases is expected to drive the market growth. In addition, an increase in the demand for less expensive drugs to manage medical conditions associated with the cardiovascular system positively affects the market. The rise in healthcare expenditure in developing countries further extends profitable opportunities to the market players. https://www.databridgemarketresearch.com/reports/global-lisinopril-market Data Bridge Market Research analyzes that the global lisinopril market, which was USD 217.1 million in 2022, would rocket up to USD 303.64 million by 2030, and is expected to undergo a CAGR of 4.30% during the forecast period. “Hospitals” dominates the end-users segment of the market owing to the increasing cases in hospitals. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

2. Report Description Market Definition Lisinopril is the anhydrous form of a long-acting Angiotensin-Converting Enzyme (ACE) inhibitor with anti-hypertensive activity. It is a peptide derivative that inhibits ACE and competitively binds to ACE, ultimately bocking the conversion of angiotensin I to angiotensin II. The common side effects of Lisinopril are headache, dizziness, persistent cough, low blood pressure, and chest pain among others. Drivers Increase in the incidence of chronic diseases The rise in the incidence of chronic diseases such as cardiovascular diseases and the availability of effective products of the companies involved in R&D of lisinopril accelerate the market growth. An increase in the prevalence of hypertension, heart failure, heart attack, strokes, diabetic kidney disease, and other diseases further increases the risk of a heart attack or stroke, resulting in a significant margin in the rise of lisinopril usage. Rise in the geriatric population Expanding geriatric population worldwide is predicted to favor lisinopril as this population is more prone to develop diseases. The population above 65 years is projected to double in the coming years. Old age people are prone to various chronic diseases such as cardiovascular diseases, endovascular diseases, and infectious diseases, which can foster the demand for lisinopril cases across the globe. According to the U.N., there were around 382 million old age people aged 60 years or above across the globe in 2017 and this number is expected to increase by 2.1 billion by 2050.

3. Market Overview Restraint/Challenge Drug recall due to product complaints Drug recall due to product complaints indicating foreign material embedded in the dose is expected to restrain market growth in the above-mentioned projected timeframe. Moreover, side effects associated with the drug are projected to become the biggest and foremost challenge for market growth in the forecast period of 2023-2030. The global lisinopril market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lisinopril market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth. Recent Development In August 2020, Sun Pharma announced that the company had launched U.S. recalls of blood pressure, epilepsy meds. Lupin's U.S. arm would pull one lot of 10 mg lisinopril tablets in the United States, citing 20 mg tablets found in at least one bottle. This voluntary recall affects more than 11,000 bottles.

4. Key Players • Some of the major players operating in the global lisinopril market are: • Lupin Pharmaceuticals, Inc. (India) • AstraZeneca (U.K.) • Merck & Co., Inc. (U.S.) • Sun Pharmaceutical Industries Limited (India) • Teva Pharmaceutical Industries Limited (Israel) • Cipla Inc. (India) • Apotex Inc. (Canada) • Aurobindo Pharma Ltd. (India) • Vitaris Inc. (U.S.) • Hikma Pharmaceutical PLC. (U.K.) • Pfizer Inc. (U.S.) • Bausch Health Companies, Inc. (Canada) • AbbVie Inc. (U.S.) • Torrent Pharmaceuticals (India) • ZydusCadila (India) • Amneal Pharmaceutical Inc. (U.S.)

5. About Data Bridge Market Research An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth  the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Read Continue : http://databridgemarketresearch.com/about-us/ Contact Us : SopanGedam Sopan.gedam@databridgemarketresearch.com